Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
18.63
-1.19 (-6.00%)
At close: Apr 28, 2026, 4:00 PM EDT
18.60
-0.03 (-0.16%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Tandem Diabetes Care Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Tandem Diabetes Care stock have an average target of 28, with a low estimate of 12 and a high estimate of 55. The average target predicts an increase of 50.30% from the current stock price of 18.63.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tandem Diabetes Care stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Hold | 11 | 10 | 11 | 12 | 9 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 19 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $25 → $28 | Strong Buy | Maintains | $25 → $28 | +50.30% | Apr 20, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $28 → $25 | Hold | Maintains | $28 → $25 | +34.19% | Apr 9, 2026 |
| Truist Securities | Truist Securities | Hold → Strong Buy Upgrades $27 → $35 | Hold → Strong Buy | Upgrades | $27 → $35 | +87.87% | Mar 19, 2026 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $21 → $33 | Hold → Buy | Upgrades | $21 → $33 | +77.13% | Mar 17, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $23 → $25 | Hold | Maintains | $23 → $25 | +34.19% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
1.10B
from 1.01B
Increased by 8.11%
Revenue Next Year
1.23B
from 1.10B
Increased by 11.85%
EPS This Year
-0.76
from -3.04
EPS Next Year
-0.04
from -0.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.4B | ||||||
| Avg | 1.1B | 1.2B | ||||||
| Low | 1.0B | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 12.0% | 24.0% | ||||||
| Avg | 8.1% | 11.9% | ||||||
| Low | 2.9% | 2.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.42 | 0.58 | ||||||
| Avg | -0.76 | -0.04 | ||||||
| Low | -1.12 | -1.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.